Iguratimod Plus Low-dose Rituximab vs Low-dose Rituximab in Corticosteroid-resistant or Relapsed ITP
Key facts
- Where
- Beijing, ChinaSee the site
- Phase
- Phase 2
Could this be for you?
Answer for yourself. This is not a decision: only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
Source: NCT07057778, who can take part
Where in China
- Peking University Insititute of HematologyBeijing, ChinaContact: Xiaohui ZhangNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Peking University People's Hospital
- Trial code
- NCT07057778
- Record updated
- 10 July 2025
- Original description
Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and Iguratimod in patients with steroid-resistant/relapsed ITP.Read full original descriptionShow less
Randomized, open-label, multicentre study to assess the efficacy and safety of the combination of low-dose rituximab and Iguratimod in patients with steroid-resistant/relapsed ITP.
Inclusion: ITP confirmed by excluding other supervened causes of thrombocytopenia; Platelet count of less than 30×10\^9/L at enrollment; Patients who did not achieve a sustained response to treatment with full dose corticosteroids for a minimum duration of 4 weeks or who relapsed during steroid-tapering or after its discontinuation.
Exclusion: Patients with other diseases were undergoing treatment with immunosuppressants; Patients with ITP had received rituximab; Secondary immune thrombocytopenia (e.g., patients with HIV, HCV, Helicobacter pylori infection or patients with systemic lupus erythematosus); Congestive heart failure; Severe arrhythmia; Active or previous malignancy; Aspartate aminotransferase and alanine transaminase levels ≥ 3×the upper limit of the normal threshold criteria; Creatinine or serum bilirubin levels each 1•5 times or more than the normal range; Nursing or pregnant women.